Diabetic Eye Disease Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036

Market Overview:

The 7 major diabetic eye disease markets reached a value of USD 4,221.1 Million in 2025. Looking forward, IMARC Group expects the 7MM to reach USD 7,906.3 Million by ​2036​, exhibiting a growth rate (CAGR) of 5.69% during ​2026-2036​.

The diabetic eye disease market has been comprehensively analyzed in IMARC's new report titled "Diabetic Eye Disease Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook ​2026-2036​". Diabetic eye disease refers to a group of vision disorders that can impact individuals with diabetes. These conditions include diabetic retinopathy, diabetic macular edema, cataracts, and glaucoma. Diabetes may impair the eyes over time, leading to impaired eyesight or blindness. Symptoms of diabetic eye disease may develop over time and include blurred vision, pain in the eye, headaches, floaters (dark spots or strings in the vision), changing vision, halos around light, diminished color vision, and, in advanced cases, partial or complete loss of vision. Signs may be mild or nonexistent in the early stages, and therefore regular eye examinations are important for detection. Diagnosis is most often established with a thorough dilated eye exam by an optometrist or ophthalmologist. This exam allows for an extensive look at the retina and the identification of blood vessel defects, edema, or hemorrhage. Optical coherence tomography (OCT) and fluorescein angiography can be conducted to determine the extent of damage to the retina.

To get more information on this market, Request Sample

The escalating prevalence of high blood sugar levels that can damage the tiny blood vessels in the retina, leading to swelling, leakage, and the growth of new, abnormal blood vessels, is primarily driving the diabetic eye disease market. In addition to this, the inflating utilization of corticosteroid injections or implants to reduce inflammation and retinal swelling in cases of diabetic macular edema, is also creating a positive outlook for the market. Moreover, the widespread adoption of laser photocoagulation technique, since it can help to seal leaking blood vessels or reduce the growth of abnormal ones, thereby preventing further damage to the retina, is bolstering the market growth. Apart from this, the rising usage of anti-VEGF (vascular endothelial growth factor) medications, which can be injected into the eye to reduce swelling and prevent the growth of new, abnormal blood vessels, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of vitrectomy that involves removing the vitreous gel and replacing it with a clear solution, is expected to drive the diabetic eye disease market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the diabetic eye disease market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for diabetic eye disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the diabetic eye disease market in any manner.

Recent Developments:

In April 2025, Regeneron Pharmaceuticals, Inc. announced that the United States FDA had issued a complete response letter (CRL) regarding the supplemental biologics license application for the addition of extended dosing intervals (up to every 24 weeks) for EYLEA HD (aflibercept) injection 8 mg across all approved indications. EYLEA HD is licensed for dosing every 8 to 16 weeks for patients with wet age-related macular degeneration and diabetic macular edema, and every 8 to 12 weeks for diabetic retinopathy, after three initial monthly doses.

In October 2024, Genentech announced positive topline one-year results from the open-label, single-arm Phase IV ELEVATUM study evaluating Vabysmo (faricimab-svoa) for the treatment of diabetic macular edema in people from racial and ethnic groups that are often underrepresented in clinical trials. The ELEVATUM study revealed clinically significant improvement in vision and reduction in retinal fluid in persons with diabetic macular edema treated with Vabysmo.

Drugs:

Lucentis (ranibizumab) is a recombinant humanized monoclonal antibody and VEGF-A antagonist used to treat macular edema caused by retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema. The drug works by targeting and blocking VEGF-A, a protein that promotes the growth of new blood vessels and vascular permeability in the retina. By inhibiting VEGF-A, Lucentis helps to reduce these abnormal processes, which can lead to vision loss in diabetic eye disease.

Eylea (aflibercept) is a VEGF inhibitor used to treat neovascular (wet) age-related macular degeneration, various types of macular edema and diabetic retinopathy. The drug treats diabetic eye disease by inhibiting the action of VEGF-A and placental growth factor (PIGF), two proteins that promote the formation of new blood vessels and the leakage of fluid into the eye. Eylea inhibits the formation of aberrant blood vessels and controls leakage and swelling in the retina, which can occur in disorders such as diabetic retinopathy and diabetic macular edema.

Vabysmo (faricimab-svoa) is a bispecific monoclonal antibody that treats diabetic eye disease by targeting two key pathways: VEGF-A and angiopoietin-2 (Ang-2). By inhibiting VEGF-A, it reduces abnormal blood vessel growth and leakage. Simultaneously, blocking Ang-2 stabilizes blood vessels and decreases inflammation. This dual mechanism helps control retinal swelling and neovascularization more effectively, leading to improved vision and extended treatment durability in diabetic macular edema and retinopathy.

BI 765128 is an investigational intravitreal therapy developed by Boehringer Ingelheim for treating diabetic macular ischemia. This drug is being evaluated for its potential to improve retinal perfusion and visual outcomes in patients with diabetic macular ischemia. It is administered through the intravitreal route. The ongoing Phase I/IIa PARTRIDGE study aims to assess the safety and efficacy of this novel agent.

PAN-90806 is a highly potent and selective inhibitor of VEGF receptor signaling. VEGF is a protein that is essential for angiogenesis (the development of new blood vessels) and enhanced permeability (blood vessel leaking), both of which contribute to the visual loss associated with neovascular age-related macular degeneration. In pre-clinical studies with validated ocular angiogenesis models, topically applied PAN-90806 in the form of an eye drop inhibited the creation of new blood vessels.

Time Period of the Study

• Base Year: 2025
• Historical Period: ​2020-2025​
• Market Forecast: ​2026-2036​

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the diabetic eye disease market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the diabetic eye disease market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current diabetic eye disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the diabetic eye disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2025 and how are they expected to perform till 2036?
• What was the country-wise size of the diabetic eye disease market across the seven major markets in 2025 and what will it look like in 2036?
• What is the growth rate of the diabetic eye disease market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2020-2036​) of diabetic eye disease across the seven major markets?
• What is the number of prevalent cases (​2020-2036​) of diabetic eye disease by age across the seven major markets?
• What is the number of prevalent cases (​2020-2036​) of diabetic eye disease by gender across the seven major markets?
• How many patients are diagnosed (​2020-2036​) with diabetic eye disease across the seven major markets?
• What is the size of the diabetic eye disease patient pool (​2020-2025​) across the seven major markets?
• What would be the forecasted patient pool (​2026-2036​) across the seven major markets?
• What are the key factors driving the epidemiological trend of diabetic eye disease?
• What will be the growth rate of patients across the seven major markets?

Diabetic Eye Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for diabetic eye disease drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the diabetic eye disease market?
• What are the key regulatory events related to the diabetic eye disease market?
• What is the structure of clinical trial landscape by status related to the diabetic eye disease market?
• What is the structure of clinical trial landscape by phase related to the diabetic eye disease market?
• What is the structure of clinical trial landscape by route of administration related to the diabetic eye disease market?